Checkpoint inhibitors flourishKey publications from the past year have enhanced our understanding of immunomodulatory drugs for advanced and metastatic skin cancers. Others could portend significant practice changes in areas such as sentinel lymph node (SLN) biopsy, says one dermatologist
Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Uro Pipeline: Data from mUC combination therapy suggests efficacy, safetyOther pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
FDA expands Opdivo use for metastatic melanomaFDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with metastatic melanoma.
FDA expands use of melanoma drugThe FDA this week expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma - lowering the risk that melanoma will return following surgery.
First 2-drug combo for advanced melanoma, plus 5 more FDA actionsFirst 2-drug therapy approved for advanced melanoma and four other recent approvals by FDA relating to new drugs and treatments.
Rapid responders may offer clues to optimize immune therapySome patients respond more rapidly to immune therapies like ipilimumab, and clinicians have observed delayed toxicities with prolonged use of checkpoint inhibitors; effective treatments for subtypes of melanoma, such as uveal melanoma, have not yet emerged.
Combo therapy yields intriguing results in melanoma progressionResults of a new study on combination drugs used to treat melanoma were presented at the 2015 American Society of Clinical Oncology meeting in Chicago. Researchers showed that a combination of ipilimumab and nivolumab stopped the advancement of melanoma for nearly a year in 58% of cases.
Targeted therapy and adoptive T-cell therapy offer alternatives to immunotherapyOther strategies such as adoptive T-cell therapy are initiated when immune therapies fail to stop disease progression in advanced melanoma.
Mutations influence CTLA-4 blockade responseA new study suggests that patients whose melanoma tumors have a high number of genetic mutations might respond best to drugs that block CTLA-4.